(Reuters) - The Food and Drug Administration advisory panel on
Wednesday unanimously recommended Zimulti not be approved
because of concerns it may increase suicidal thinking and
depression. The FDA is expected to make a final decision by
July 26.
"The bar for approval in the area of obesity has been
raised," Bank of America analyst William Ho said of the ruling
in a research note.
Read more at Reuters.com Government Filings News
Wednesday unanimously recommended Zimulti not be approved
because of concerns it may increase suicidal thinking and
depression. The FDA is expected to make a final decision by
July 26.
"The bar for approval in the area of obesity has been
raised," Bank of America analyst William Ho said of the ruling
in a research note.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment